Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration

por Schilter, Heidi C, Collison, Adam, Russo, Remo C, Foot, Jonathan S, Yow, Tin T, Vieira, Angelica T, Tavares, Livia D, Mattes, Joerg, Teixeira, Mauro M, Jarolimek, Wolfgang
Publicado 2015

Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer

por Chang, Joan, Lucas, Morghan C., Leonte, Lidia E., Garcia-Montolio, Marc, Singh, Lukram Babloo, Findlay, Alison D., Deodhar, Mandar, Foot, Jonathan S., Jarolimek, Wolfgang, Timpson, Paul, Erler, Janine T., Cox, Thomas R.
Publicado 2017

The lysyl oxidase like 2/3 enzymatic inhibitor, PXS‐5153A, reduces crosslinks and ameliorates fibrosis

por Schilter, Heidi, Findlay, Alison D., Perryman, Lara, Yow, Tin T., Moses, Joshua, Zahoor, Amna, Turner, Craig I., Deodhar, Mandar, Foot, Jonathan S., Zhou, Wenbin, Greco, Angelique, Joshi, Amar, Rayner, Benjamin, Townsend, Sarah, Buson, Alberto, Jarolimek, Wolfgang
Publicado 2018

An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies

por Findlay, Alison, Turner, Craig, Schilter, Heidi, Deodhar, Mandar, Zhou, Wenbin, Perryman, Lara, Foot, Jonathan, Zahoor, Amna, Yao, Yimin, Hamilton, Ross, Brock, Mary, Raso, Christina, Stolp, Jessica, Galati, Marie, Hamprecht, Dieter, Charlton, Brett, Jarolimek, Wolfgang
Publicado 2021